1-(4-carboxyphenyl)-3,3-dimethyltriazene has been researched along with Leukemia L 1210 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hansch, C; Hatheway, GJ; Kim, KH; Milstein, SR; Quinn, FR; Schmidt, CL; Smith, RN | 1 |
| Benvenuto, J; Farquhar, D | 1 |
2 other study(ies) available for 1-(4-carboxyphenyl)-3,3-dimethyltriazene and Leukemia L 1210
| Article | Year |
|---|---|
Antitumor 1-(X-aryl)-3,3-dialkyltriazenes. 1. Quantitative structure-activity relationships vs. L1210 leukemia in mice.
Topics: Animals; Antineoplastic Agents; Isomerism; Kinetics; Leukemia L1210; Mice; Structure-Activity Relationship; Triazenes | 1978 |
1-Aryl-3,3-dimethyltriazenes: potential central nervous system active analogues of 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (DTIC).
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Dacarbazine; Drug Evaluation, Preclinical; Ependymoma; Leukemia L1210; Melanoma; Mice; Mice, Inbred Strains; Structure-Activity Relationship | 1984 |